New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 11, 2010, Pages 1622-1636

  Müllertz, Anette ^a,b   Ogbonna, Anayo ^a   Ren, Shan ^a   Rades, Thomas ^c  

^a Department of Pharmaceutics and Analytical Chemistry ^*  (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

lipid and surfactant based drug delivery systems; lipolysis; poorly soluble drug

Indexed keywords

ALFACALCIDOL; ALPHA TOCOPHEROL; AMPRENAVIR; BEXAROTENE; CALCITRIOL; CIPROFLOXACIN; CLOFAZIMINE; CLOMETHIAZOLE; CYCLOSPORIN A; DETRO; DIACYLGLYCEROL; DOXERCALCIFEROL; DRONABINOL; DUTASTERIDE; EFAVIRENZ; EPADEL; EXCIPIENT; FENOFIBRATE; FENOGAL; IBUDILAST; INDOMETACIN FARNESIL; ISOTRETINOIN; LIPID; LOPINAVIR PLUS RITONAVIR; MENATETRENONE; MONOACYLGLYCEROL; MORPHINE SULFATE; OIL; PARICALCITOL; PROGESTERONE; RAPAMYCIN; RETINOIC ACID; RITONAVIR; SAQUINAVIR; SIDMARK; SOLVENT; SURFACTANT; TEPRENONE; TESTOSTERONE UNDECANOATE; TIPRANAVIR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

CLASSIFICATION; DIGESTIVE FUNCTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG RESEARCH; DRUG SOLUBILITY; EMULSION; FOOD INTAKE; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; LIPOLYSIS; PHYSICAL CHEMISTRY; PHYSICOCHEMICAL MODEL; REVIEW;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; EMULSIONS; LIPIDS; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; SURFACE-ACTIVE AGENTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 78049499869     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01107.x     Document Type: Review

References (76)

1. Gursoy RN, Benita S,. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004; 58: 173-182.
2. Kommuru TR, et al. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm 2001; 212: 233-246.
3. Pouton CW, Porter CJ,. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev 2008; 60: 625-637.
4. O'Driscoll CM, Griffin BT,. Biopharmaceutical challenges associated with drugs with low aqueous solubility: the potential impact of lipid-based formulations. Adv Drug Deliv Rev 2008; 60: 617-624.
5. Yu LX, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res 2002; 19: 921-925.
6. Amidon GL, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vitro bioavailability. Pharm Res 1995; 12: 413-420.
7. Forster A, et al. Characterization of glass solutions of poorly water-soluble drugs produced by melt extrusion with hydrophilic amorphous polymers. J Pharm Pharmacol 2001; 53: 303-315.
8. Heinz A, et al. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy. J Pharm Pharmacol 2009; 61: 971-988.
9. Chakraborty S, et al. Lipid: an emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm 2009; 73: 1-15.
10. Gershanik T, Benita S,. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm 2000; 50: 179-188.
11. Fatouros DG, et al. Morphological observations on a lipid-based drug delivery system during in vitro digestion. Eur J Pharm Sci 2007; 31: 85-94.
12. Kossena GA, et al. Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water-soluble drug. J Pharm Sci 2005; 94: 481-492.
13. De Smidt PC, et al. Intestinal absorption of penclomedine from lipid vehicles in the conscious rat: contribution of emulsification versus digestibility. Int J Pharm 2004; 270: 109-118.
14. Schiller C, et al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2005; 22: 971-979.
15. Kleberg K, et al. Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies. J Pharm Pharmacol 2010; 62: 1656-1668.
16. Kossena GA, et al. Low dose lipid formulations: effects on gastric emptying and biliary secretion. Pharm Res 2007; 24: 2084-2096.
17. Carriere F, et al. Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans. Gastroenterology 1993; 105: 876-888.
18. Fernandez S, et al. Comparative study on digestive lipase activities on the self emulsifying excipient Labrasol, medium chain glycerides and PEG esters. Biochim Biophys Acta 2007; 1771: 633-640.
19. Fernandez S, et al. Lipolysis of the semi-solid self-emulsifying excipient Gelucire 44/14 by digestive lipases. Biochim Biophys Acta 2008; 1781: 367-375.
20. Staggers JE, et al. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption 1. phasebehavior and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human-beings. Biochemistry 1990; 29: 2028-2040.
21. Boyd BJ, et al. Nonlamellar liquid crystalline nanostructured particles: advances in materials and structure determination. J Liposome Res 2009; 19: 12-28.
22. Dahan A, Hoffman A,. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release 2008; 129: 1-10.
23. Porter CJ, et al. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev 2008; 60: 673-691.
24. Chistie WW,. High Performance Liquid Chromatography and Lipids: a Practical Guide. Oxford: Pergamon Press, 1987.
25. Small DM,. A classification of biologic lipids based upon their interaction in aqeous systems. J Am Oil Chem Soc 1968; 45: 108-119.
26. Mori S, et al. Studies on the intestinal absorption of low molecular weight heparin using saturated fatty acids and their derivatives as an absorption enhancer in rats. Bio Pharm Bull 2004; 27: 418-421. (Pubitemid 41685491)
27. Strickley RG,. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004; 21: 201-230.
28. Pouton CW,. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci 2000; 11 (Suppl. 2): S93-S98.
29. Pouton CW,. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 2006; 29: 278-287.
30. Strickley RG,. Currently marketed oral lipid-based dosage forms: drug products and excipients. In:, Hauss DJ, ed. Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water- Soluble Drugs. New York: Informa Healthcare, 2007: 1-31.
31. Physicians' Desk Reference, 62nd edn. Montvale: Thomson Healthcare, 2008.
32. Charman SA, et al. Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res 1992; 9: 87-93.
33. Wakerley MG, et al. The effect of surfactant HLB on the self-emulsifying efficiency of nonionic surfactant-vegetable oil mixtures. J Pharm Pharmacol 1986; 38: 2P.
34. Cuine JF, et al. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J Pharm Sci 2008; 97: 995-1012.
35. Gershanik T, Benita S,. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm 2000; 50: 179-188.
36. Grove M, et al. Bioavailability of seocalcitol II. Development and characterisation of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides. Eur J Pharm Sci 2006; 28: 233-242.
37. Kang BK, et al. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm 2004; 274: 65-73.
38. Mandawgade SD, et al. Development of SMEDDS using natural lipophile: application to beta-artemether delivery. Int J Pharm 2008; 362: 179-183.
39. Singh AK, et al. Exemestane loaded self-microemulsifying drug delivery system (SMEDDS): development and optimization. AAPS PharmSciTech 2008; 9: 628-634.
40. Gursoy RN, Benita S,. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004; 58: 173-182.
41. Vonderscher J, Meinzer A,. Rationale for the development of Sandimmune-Neoral. Transplant Proc 1994; 26: 2925-2927.
42. Tarr BD, Yalkowsky SH,. Enhanced intestinal-absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm Res 1989; 6: 40-43.
43. Gao ZG, et al. Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporin A. Int J Pharm 1998; 161: 75-86.
44. Mohsin K, et al. Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution. J Pharm Sci 2009; 98: 3582-3595.
45. Tonsberg H, et al. Effects of polysorbate 80 on the in vitro precipitation and oral bioavailability of halofantrine from polyethylene glycol 400 formulations in rats. J Pharm Pharmacol 2009; 62: 63-70.
46. Brouwers J, et al. Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir. J Pharm Sci 2006; 95: 372-383.
47. Wood R, et al. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2004; 48: 116-123.
48. Small DM,. A classification of biologic lipids based upon their interaction in aqueous systems. J Am Oil Chem Soc 1968; 45: 108-119.
49. Gradzielski M, Hoffman H,. Rheological properties of microemulsion. In:, Kumar P, Mittal KL, eds. Handbook of Micro-emulsion Science and Technology. New York: Marcel Dekker, 1999: 357-386.
50. Constantinides PP,. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res 1995; 12: 1561-1572.
51. Greiner RW, Evans DF,. Spontaneous formation of a water-continuous emulsion from water-in-oil microemulsion. Langmuir 1990; 6: 1793-1796.
52. Zhao Y, et al. Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of Zedoary essential oil: formulation and bioavailability studies. Int J Pharm 2010; 383: 170-177.
53. Kaukonen AM, et al. Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations. Pharm Res 2004; 21: 245-253.
54. Zangenberg NH, et al. A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium. Eur J Pharm Sci 2001; 14: 115-122.
55. Zangenberg NH, et al. A dynamic in vitro lipolysis model. II: Evaluation of the model. Eur J Pharm Sci 2001; 14: 237-244.
56. Fatouros DG, et al. Structural development of self nano emulsifying drug delivery systems (SNEDDS) during in vitro lipid digestion monitored by small-angle X-ray scattering. Pharm Res 2007; 24: 1844-1853.
57. Fatouros DG, et al. In vitro-in vivo correlations of self-emulsifying drug delivery systems combining the dynamic lipolysis model and neuro-fuzzy networks. Eur J Pharm Biopharm 2008; 69: 887-898.
58. Larsen A, et al. Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vitro bioavailability and dynamic in vitro lipolysis. Pharm Res 2008; 25: 2769-2777.
59. Mohsin K, et al. Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution. J Pharm Sci 2009; 98: 3582-3595.
60. Sek L, et al. Examination of the impact of a range of Pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone. J Pharm Pharmacol 2006; 58: 809-820.
61. Larsen A, et al. Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vitro bioavailability and dynamic in vitro lipolysis. Pharm Res 2008; 25: 2769-2777.
62. Nielsen FS, et al. Bioavailability of probucol from lipid and surfactant based formulations in minipigs: influence of droplet size and dietary state. Eur J Pharm Biopharm 2008; 69: 553-562.
63. Vinson PK, et al. Vesicle-micelle transition of phosphatidylcholine and octyl glucoside elucidated by cryo-transmission electron microscopy. Biophys J 1989; 56: 669-681.
64. Walter A, et al. Intermediate structures in the cholatephosphatidylcholine vesicle-micelle transition. Biophys J 1991; 60: 1315-1325.
65. Subramanian N, et al. Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol Pharm Bull 2004; 27: 1993-1999.
66. Lee JM, et al. Microemulsion formulation of clonixic acid: solubility enhancement and pain reduction. J Pharm Pharmacol 2002; 54: 43-49.
67. Cui J, et al. Enhancement of oral absorption of curcumin by selfmicroemulsifying drug delivery systems. Int J Pharm 2009; 371: 148-155.
68. Nielsen FS, et al. Characterization of prototype self-nanoemulsifying formulations of lipophilic compounds. J Pharm Sci 2007; 96: 876-892.
69. Porter CJH, et al. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm Res 2004; 21: 1405-1412.
70. Patel AR, Vavia PR,. Preparation and in vitro evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate. AAPS J 2007; 9: E344-E352.
71. Arida AI, et al. Improving the high variable bioavailability of griseofulvin by SEDDS. Chem Pharm Bull 2007; 55: 1713-1719.
72. Khoo SM, et al. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm 1998; 167: 155-164.
73. Liu Y, et al. Optimization and in situ intestinal absorption of self-microemulsifying drug delivery system of oridonin. Int J Pharm 2009; 365: 136-142.
74. Quan DQ, et al. Studies on preparation and absolute bioavailability of a self-emulsifying system containing puerarin. Chem Pharm Bull 2007; 55: 800-803.
75. Grove M, et al. Bioavailability of seocalcitol III. Administration of lipid-based formulations to minipigs in the fasted and fed state. Eur J Pharm Sci 2007; 31: 8-15.
76. Elnaggar YS, et al. Self-nanoemulsifying drug delivery systems of tamoxifen citrate: design and optimization. Int J Pharm 2009; 380: 133-141.